Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs.

Adams DJ, Dai M, Pellegrino G, Wagner BK, Stern AM, Shamji AF, Schreiber SL.

Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15115-20. Epub 2012 Sep 4.


Discovery of small-molecule enhancers of reactive oxygen species that are nontoxic or cause genotype-selective cell death.

Adams DJ, Boskovic ZV, Theriault JR, Wang AJ, Stern AM, Wagner BK, Shamji AF, Schreiber SL.

ACS Chem Biol. 2013 May 17;8(5):923-9. doi: 10.1021/cb300653v. Epub 2013 Mar 25.


Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.

Roh JL, Kim EH, Park JY, Kim JW, Kwon M, Lee BH.

Oncotarget. 2014 Oct 15;5(19):9227-38.


Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents.

Wu Y, Min X, Zhuang C, Li J, Yu Z, Dong G, Yao J, Wang S, Liu Y, Wu S, Zhu S, Sheng C, Wei Y, Zhang H, Zhang W, Miao Z.

Eur J Med Chem. 2014 Jul 23;82:545-51. doi: 10.1016/j.ejmech.2014.05.070. Epub 2014 Jun 2.


Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.

Punganuru SR, Madala HR, Venugopal SN, Samala R, Mikelis C, Srivenugopal KS.

Eur J Med Chem. 2016 Jan 1;107:233-44. doi: 10.1016/j.ejmech.2015.10.052. Epub 2015 Nov 2.


Selective killing of cancer cells by a small molecule targeting the stress response to ROS.

Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, Lee SW.

Nature. 2011 Jul 13;475(7355):231-4. doi: 10.1038/nature10167. Erratum in: Nature. 2012 Jan 26;481(7382):534. Nature. 2015 Oct 22;526(7574):596.


Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells.

Kim TH, Song J, Kim SH, Parikh AK, Mo X, Palanichamy K, Kaur B, Yu J, Yoon SO, Nakano I, Kwon CH.

Neuro Oncol. 2014 Oct;16(10):1354-64. doi: 10.1093/neuonc/nou088. Epub 2014 May 30.


Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (review).

Möhler H, Pfirrmann RW, Frei K.

Int J Oncol. 2014 Oct;45(4):1329-36. doi: 10.3892/ijo.2014.2566. Epub 2014 Jul 28. Review.


Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation.

Liu JM, Pan F, Li L, Liu QR, Chen Y, Xiong XX, Cheng K, Yu SB, Shi Z, Yu AC, Chen XQ.

Biochem Biophys Res Commun. 2013 Jul 19;437(1):87-93. doi: 10.1016/j.bbrc.2013.06.042. Epub 2013 Jun 22.


Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer.

Zou P, Xia Y, Ji J, Chen W, Zhang J, Chen X, Rajamanickam V, Chen G, Wang Z, Chen L, Wang Y, Yang S, Liang G.

Cancer Lett. 2016 May 28;375(1):114-26. doi: 10.1016/j.canlet.2016.02.058. Epub 2016 Mar 7.


Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.

Xiong XX, Liu JM, Qiu XY, Pan F, Yu SB, Chen XQ.

Acta Pharmacol Sin. 2015 Mar;36(3):362-74. doi: 10.1038/aps.2014.141. Epub 2015 Jan 26.


Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.

Jarvius M, Fryknäs M, D'Arcy P, Sun C, Rickardson L, Gullbo J, Haglund C, Nygren P, Linder S, Larsson R.

Biochem Biophys Res Commun. 2013 Feb 8;431(2):117-23. doi: 10.1016/j.bbrc.2013.01.017. Epub 2013 Jan 11.


Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine.

Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD.

J Biol Chem. 2017 Jan 6;292(1):112-120. doi: 10.1074/jbc.M116.750299. Epub 2016 Nov 21.


Synthesis of piperlogs and analysis of their effects on cells.

Boskovic ZV, Hussain MM, Adams DJ, Dai M, Schreiber SL.

Tetrahedron. 2013 Sep 9;69(36). doi: 10.1016/j.tet.2013.05.080.


Piperlongumine derived cyclic sulfonamides (sultams): Synthesis and in vitro exploration for therapeutic potential against HeLa cancer cell lines.

Lad NP, Kulkarni S, Sharma R, Mascarenhas M, Kulkarni MR, Pandit SS.

Eur J Med Chem. 2017 Jan 27;126:870-878. doi: 10.1016/j.ejmech.2016.12.022. Epub 2016 Dec 10.


Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity.

Niu M, Xu X, Shen Y, Yao Y, Qiao J, Zhu F, Zeng L, Liu X, Xu K.

Chem Biol Interact. 2015 Jul 25;237:66-72. doi: 10.1016/j.cbi.2015.05.016. Epub 2015 May 28.


Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import.

Niu M, Shen Y, Xu X, Yao Y, Fu C, Yan Z, Wu Q, Cao J, Sang W, Zeng L, Li Z, Liu X, Xu K.

Biochem Biophys Res Commun. 2015 Jul 10;462(4):326-31. doi: 10.1016/j.bbrc.2015.04.136. Epub 2015 May 13.


Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells.

Minelli A, Bellezza I, Tucci A, Rambotti MG, Conte C, Culig Z.

Prostate. 2009 Apr 1;69(5):538-47. doi: 10.1002/pros.20900.


Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.

Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey JA, Montalto G, Cervello M.

Mol Pharmacol. 2009 Aug;76(2):290-300. doi: 10.1124/mol.109.055418. Epub 2009 May 20.


Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.

Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R.

Cancer Res. 1999 May 15;59(10):2493-8.

Supplemental Content

Support Center